US Patent 11786544 Formulations of phosphoramidate derivatives of nucleoside drugs
Patent 11786544 was granted and assigned to NuCana on October, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 18 Oct, 2023
Golden AI
Edits made to:
Infobox (+27 properties)
Article (+519 characters)
US Patent 11786544 Formulations of phosphoramidate derivatives of nucleoside drugs
Article
Patent abstract
This invention relates to pharmaceutical formulations and formulation strategies of protides (phosphoramidate derivatives of nucleosides) and, in particular, protides useful in the treatment of cancer such as NUC-3373 (5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate) and NUC-7738 (3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate). In particular, the invention relates to formulations which comprise a polar aprotic solvent, for example dimethyl acetamide (DMA).
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Gordon Kennovin
Hugh Griffith
Date of Patent
October 17, 2023
Patent Application Number
17231606
Date Filed
April 15, 2021
Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11786544 Formulations of phosphoramidate derivatives of nucleoside drugs
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
